Dr. Colin P. Dinney, MD

Dr. Dinney practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Dinney's NPI, 1700984630, was assigned on September 21, 2006. Dr. Dinney graduated from University of Manitoba in 1982. Dr. Dinney holds Texas license H8920.

Dr. Dinney's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Dinney's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dinney practices. Vendor and product names are available with a free account.

Urology is Dr. Dinney's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dmand AI has Dr. Dinney's licenses on file in 3 states: Texas, Florida and Oklahoma.

Dmand AI lists bladder removal, enlarged prostate, prostate cancer, urinary endoscopy and urinary tract infection among the conditions Dr. Dinney treats.

CMS data shows 89 Medicare services from Dr. Dinney across 4 procedure codes in 2024, for 62 Medicare patients. Medicare paid $15,495 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 62 Medicare patients who saw Dr. Dinney in 2024. The largest group is 65 to 74, with 34 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.12, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Dinney's median patient age at 76, with 23% women.

In 2024, Dr. Dinney wrote 51 Medicare Part D claims for 33 patients. 90% of them were for generic drugs. CMS names the drug for 13 of them, across 1 drug with 11 or more claims each, at $18 in total drug cost. In 2023, CMS named 68 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Dinney for performance year 2024, reported as part of a group.

Dmand AI links 374 papers to Dr. Dinney, published from 2005 to 2025. 2017 was the busiest year, with 19. The most frequent topics are Urinary Bladder Neoplasms, Carcinoma, Transitional Cell and Cystectomy. Dr. Dinney has published most often in J Urol. Dr. Dinney's most frequent co-authors are Ashish M. Kamat, MD, Neema Navai, MD and Arlene O. Siefker-Radtke, MD.

Dmand AI links Dr. Dinney to 6 clinical trials, 3 of them phase 2 studies. Conditions studied include Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms and Urinary Bladder Diseases. M.D. Anderson Cancer Center sponsors the most, 2.

CMS Open Payments shows 34 general payments to Dr. Dinney from 7 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 57% of the total. Urogen Pharma, Inc. paid the most, $6,400.

Dmand AI lists 2 awards for Dr. Dinney, most recently Top Doctors:SE Texas in 2013.

Dr. Dinney graduated from University of Manitoba in 1982. Dr. Dinney is a member of ASCO.

Dr. Dinney is in network with 7 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. POS plans come from the most carriers, 4. Check the plan with the practice before a visit.